AimPlex Biosciences

Executive Summary

AimPlex Biosciences is a San Diego-based biotechnology company specializing in the development and provision of custom and premixed multiplex bead-based immunoassay panels for flow cytometry analysis. Founded in 2017, the company leverages deep assay development expertise to offer high-quality, cost-effective reagents for detecting a wide range of analytes, including cytokines, chemokines, and soluble CD markers. Its products are designed to work on standard flow cytometers, providing researchers with flexible and efficient solutions for biomedical testing. By focusing on customization and affordability, AimPlex has carved a niche in the competitive multiplex immunoassay market, serving academic, pharmaceutical, and clinical research customers. The company’s strong technical support and rapid turnaround times further differentiate it from larger established players. As demand for multiplexing capabilities continues to grow in immunology and diagnostics, AimPlex is well-positioned to expand its customer base and product portfolio. While the company remains private with limited public financial disclosures, its consistent product launches and positive customer reception suggest a steady growth trajectory. AimPlex’s ability to innovate in a high-growth segment of the life sciences tools market underpins its potential for sustained value creation. The following catalysts could accelerate its growth and market penetration.

Upcoming Catalysts (preview)

• Q1 2027Launch of a next-generation high-plex panel (e.g., 30+ cytokine panel) with improved sensitivity70% success
• Q4 2026Securing a strategic distribution partnership for European or Asian markets50% success
• Q3 2027FDA 510(k) clearance for a first clinical diagnostic application of its multiplex platform30% success